Clinical trial
Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage…
NCT00003732 · Rigshospitalet, Denmark, Other · Completed
Key facts
| NCT number | NCT00003732 |
|---|---|
| Title | Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Cancer |
| Official title | A Phase I/II Study to Determine the Maximum Tolerated Doses of Oral Topotecan, Carboplatin and Paclitaxel Administered Every 21 Days to Patients With Epithelial Ovarian Cancer Stages IIb, IIc, III and IV |
| Lead sponsor | Rigshospitalet, Denmark, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | carboplatin, paclitaxel, topotecan hydrochloride |
| Enrollment | 80 |
| Start date | Sep 1, 1998 |
| Completion | Sep 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Aug 12, 2013 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: